Back to Authors

Cortelli, Pietro

https://orcid.org/0000-0002-3633-8818

A5090382134 | I4210123211

Mayo Clinic

Istituto delle Scienze Neurologiche di Bologna

Citations 11

Clinical Practice Guidelines for the Diagnosis, Management, and Surveillance of LMNB1 -Related Autosomal Dominant Leukodystrophy

Neurology Genetics | August 29, 2025 | Volume: 11 | Issue: 5 | Pages: No page available

10.1212/nxg.0000000000200287 | PMID 40933505

Structural Variants at the LMNB1 Locus: Deciphering Pathomechanisms in Autosomal Dominant Adult‐Onset Demyelinating Leukodystrophy

Annals of Neurology | July 30, 2024 | Volume: 96 | Issue: 5 | Pages: 855-870

10.1002/ana.27038 | PMID 39078102

ObjectiveWe aimed to elucidate the pathogenic mechanisms underlying autosomal dominant adult‐onset demyelinating leukodystrophy (ADLD), and to understand the genotype/phenotype correlation of structural variants (SVs) in the LMNB1 locus.BackgroundSince the discovery of 3D genome architectures and topologically associating domains (TADs), new pathomechanisms have been postulated for SVs, regardless of gene dosage changes. ADLD is a rare genetic disease associated with duplications (classical ADLD) or noncoding deletions (atypical ADLD) in the LMNB1 locus.MethodsHigh‐throughput chromosome conformation capture, RNA sequencing, histopathological analyses of postmortem brain tissues, and clinical and neuroradiological investigations were performed.ResultsWe collected data from >20 families worldwide carrying SVs in the LMNB1 locus and reported strong clinical variability, even among patients carrying duplications of the entire LMNB1 gene, ranging from classical and atypical ADLD to asymptomatic carriers. We showed that patients with classic ADLD always carried intra‐TAD duplications, resulting in a simple gene dose gain. Atypical ADLD was caused by LMNB1 forebrain‐specific misexpression due to inter‐TAD deletions or duplications. The inter‐TAD duplication, which extends centromerically and crosses the 2 TAD boundaries, did not cause ADLD. Our results provide evidence that astrocytes are key players in ADLD pathology.InterpretationOur study sheds light on the 3D genome and TAD structural changes associated with SVs in the LMNB1 locus, and shows that a duplication encompassing LMNB1 is not sufficient per se to diagnose ADLD, thereby strongly affecting genetic counseling. Our study supports breaking TADs as an emerging pathogenic mechanism that should be considered when studying brain diseases. ANN NEUROL 2024;96:855–870
Predictors of Neurodegeneration in Idiopathic REM sleep behavior disorder: a multicenter cohort study (CCI.003)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.cci.003

The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy

Movement Disorders | April 21, 2022 | Volume: 37 | Issue: 6 | Pages: 1131-1148

10.1002/mds.29005 | PMID 35445419

ABSTRACT Background The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages. Objective To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence‐based and consensus‐based methodology. Methods We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis. The criteria were developed and later optimized using two Delphi rounds within the MSA Criteria Revision Task Force, a survey for MDS membership, and a virtual Consensus Conference. Results The criteria for neuropathologically established MSA remain unchanged. For a clinical MSA diagnosis a new category of clinically established MSA is introduced, aiming for maximum specificity with acceptable sensitivity. A category of clinically probable MSA is defined to enhance sensitivity while maintaining specificity. A research category of possible prodromal MSA is designed to capture patients in the earliest stages when symptoms and signs are present, but do not meet the threshold for clinically established or clinically probable MSA. Brain magnetic resonance imaging markers suggestive of MSA are required for the diagnosis of clinically established MSA. The number of research biomarkers that support all clinical diagnostic categories will likely grow. Conclusions This set of MDS MSA diagnostic criteria aims at improving the diagnostic accuracy, particularly in early disease stages. It requires validation in a prospective clinical and a clinicopathological study. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
Neuro‐Ophthalmological Findings in Early Fatal Familial Insomnia

Annals of Neurology | January 2, 2021 | Volume: 89 | Issue: 4 | Pages: 823-827

10.1002/ana.26008 | PMID 33386648

Fatal familial insomnia (FFI) is a rare inherited prion disease characterized by sleep, autonomic, and motor disturbances. Neuro‐ophthalmological abnormalities have been reported at the onset of disease, although not further characterized. We analyzed video recordings of eye movements of 6 patients with FFI from 3 unrelated kindreds, seen within 6 months from the onset of illness. Excessive saccadic intrusions were the most prominent findings. In patients with severe insomnia, striking saccadic intrusions are an early diagnostic clue for FFI. The fact that the thalamus is the first structure affected in FFI also suggests its role in the control of steady fixation. ANN NEUROL 2021;89:823–827
Brain ischemic injury in COVID‐19‐infected patients: a series of 10 post‐mortem cases

Brain Pathology | October 1, 2020 | Volume: 31 | Issue: 1 | Pages: 205-210

10.1111/bpa.12901 | PMID 33002281

Stridor in multiple system atrophy

Neurology | October 1, 2019 | Volume: 93 | Issue: 14 | Pages: 630-639

10.1212/wnl.0000000000008208 | PMID 31570638

A critique of the second consensus criteria for multiple system atrophy

Movement Disorders | April 30, 2019 | Volume: 34 | Issue: 7 | Pages: 975-984

10.1002/mds.27701 | PMID 31034671

Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study

Brain | January 26, 2019 | Volume: 142 | Issue: 3 | Pages: 744-759

10.1093/brain/awz030 | PMID 30789229

Orexin/hypocretin system and autonomic control

Neurology | December 21, 2013 | Volume: 82 | Issue: 3 | Pages: 271-278

10.1212/wnl.0000000000000045 | PMID 24363130